Longeveron Inc. (LGVN)
NASDAQ: LGVN · Real-Time Price · USD
0.7502
+0.0472 (6.71%)
Jul 1, 2026, 11:01 AM EDT - Market open
Longeveron Revenue
Longeveron had revenue of $398.00K in the quarter ending March 31, 2026, with 4.46% growth. This brings the company's revenue in the last twelve months to $1.22M, down -45.35% year-over-year. In the year 2025, Longeveron had annual revenue of $1.20M, down -49.87%.
Revenue (ttm)
$1.22M
Revenue Growth
-45.35%
P/S Ratio
18.01
Revenue / Employee
$32,000
Employees
38
Market Cap
23.37M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.20M | -1.19M | -49.87% |
| Dec 31, 2024 | 2.39M | 1.68M | 237.38% |
| Dec 31, 2023 | 709.00K | -513.00K | -41.98% |
| Dec 31, 2022 | 1.22M | -84.00K | -6.43% |
| Dec 31, 2021 | 1.31M | -4.32M | -76.80% |
| Dec 31, 2020 | 5.63M | -10.47K | -0.19% |
| Dec 31, 2019 | 5.64M | 3.50M | 164.17% |
| Dec 31, 2018 | 2.13M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Palatin Technologies | 12.88M |
| Marker Therapeutics | 3.55M |
| Lipocine | 2.00M |
| Pluri | 1.08M |
| VYNE Therapeutics | 454.00K |
| Allarity Therapeutics | 345.00K |
| Neuphoria Therapeutics | -13.27K |
LGVN News
- 13 days ago - New Phase 2a Clinical Data Analysis of Stem Cell Therapy Laromestrocel in Mild Alzheimer's Disease Accepted for Poster Presentation at the 2026 Alzheimer's Association International Conference (AAIC) - GlobeNewsWire
- 22 days ago - Longeveron granted SME status by European Medicines Agency - TheFly
- 22 days ago - Longeveron Granted Small or Medium-sized Enterprise (SME) Status by the European Medicines Agency (EMA) - GlobeNewsWire
- 27 days ago - Longeveron to Present at BIO International Convention 2026 - GlobeNewsWire
- 5 weeks ago - Longeveron Issues Letter to Stockholders Highlighting Corporate Strategy, Strategic Partnering Approach and 2026 Key Priorities - GlobeNewsWire
- 6 weeks ago - Longeveron Proxy statement: Proxy filing - Filings
- 6 weeks ago - Longeveron Proxy statement: Proxy filing - Filings
- 6 weeks ago - Longeveron reports Q1 EPS (19c) vs. (34c) last year - TheFly